FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:2576-2578 June 23, 2005 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

On November 23, 2000, the results of the Vioxx Gastrointestinal Outcomes Research study, known as VIGOR, were published in the Journal. This randomized, controlled trial showed that rofecoxib, an inhibitor of cyclooxygenase-2 that had been marketed as Vioxx since May 1999, was associated with fewer gastrointestinal complications than naproxen, a standard nonsteroidal antiinflammatory drug. Unexpectedly, the VIGOR study also showed that the patients who were given rofecoxib had four times as many myocardial infarctions as those who were given naproxen.

This finding of a significant increase in the risk of myocardial infarction was an early signal of a potentially . . . [Full Text of this Article]

Source Information

Mr. Waxman is a U.S. Representative from California.

Related Letters:

The Lessons of Vioxx
Frazier K. C., Waxman H. A.
Extract | Full Text | PDF  
N Engl J Med 2005; 353:1420-1421, Sep 29, 2005. Correspondence

This article has been cited by other articles:

• Jackevicius, C. A., Tu, J. V., Ross, J. S., Ko, D. T., Krumholz, H. M. (2008). Use of Ezetimibe in the United States and Canada. NEJM 358: 1819-1828 [Abstract] [Full Text]  
• Scott, P A, Kingsley, G H, Smith, C M, Choy, E H, Scott, D L (2007). Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis 66: 1296-1304 [Abstract] [Full Text]  
• Terre, L. (2007). Behavioral Medicine Review: The Dialectic of Tradition and Progress in Osteoarthritis Management. AMERICAN JOURNAL OF LIFESTYLE MEDICINE 1: 267-270 [Abstract]  
• Ziemer, M., Wiesend, C. L., Vetter, R., Weiss, J., Blaschke, S., Norgauer, J., Mockenhaupt, M. (2007). Cutaneous Adverse Reactions to Valdecoxib Distinct From Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Arch Dermatol 143: 711-716 [Abstract] [Full Text]  
• Lynch, J. R., Cunningham, M. R.A., Warme, W. J., Schaad, D. C., Wolf, F. M., Leopold, S. S. (2007). Commercially Funded and United States-Based Research Is More Likely to Be Published; Good-Quality Studies with Negative Outcomes Are Not. JBJS 89: 1010-1018 [Abstract] [Full Text]  
• Hershman, D., Neugut, A. I., Jacobson, J. S., Wang, J., Tsai, W.-Y., McBride, R., Bennett, C. L., Grann, V. R. (2007). Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy. JNCI J Natl Cancer Inst 99: 196-205 [Abstract] [Full Text]  
• Brown, S. D., Daly, J. C., Kalish, L. A., McDaniel, S. A. (2006). Financial Disclosures of Scientific Papers Presented at the 2003 RSNA Annual Meeting: Association with Reporting of Non-Food and Drug Administration-approved Uses of Industry Products. Radiology 239: 849-855 [Abstract] [Full Text]  
• Markel, H. (2005). Why America Needs a Strong FDA. JAMA 294: 2489-2491 [Full Text]  
• O'Rourke, M. F. (2005). Beyond Blood Pressure: Subtle Effects of Drug Classes. Arterioscler. Thromb. Vasc. Bio. 25: 2238-2239 [Full Text]  
• Frazier, K. C., Waxman, H. A. (2005). The lessons of Vioxx.. NEJM 353: 1420-1421 [Full Text]  
• Antman, E. M., DeMets, D., Loscalzo, J. (2005). Cyclooxygenase Inhibition and Cardiovascular Risk. Circulation 112: 759-770 [Full Text]